Photoreceptor outer segments are described as the light-sensitive antennae of photoreceptor cells. They are continuously renewed throughout a person’s life: each day, photoreceptors add dozens of new disc-shaped membranes containing photopigment to the outer segment while discarding old ones. These membranes must be folded into flat layers and packed precisely, a process Spencer compared to intricate origami. The arrangement maximizes the efficiency of light capture. Earlier work from Spencer’s laboratory found that the proteins produced by PRCD and KIAA1549 participate in the first steps of constructing the membrane material packed inside outer segments. Without these proteins, the membranes are folded and packed in a highly disorganized fashion, leading to cell dysfunction, cell death and blindness.

The five-year award has two specific aims. The first will examine the molecular mechanism through which PRCD keeps the outer segment’s membrane layers tightly adhered during the earliest stages of their morphogenesis. The second will examine how KIAA1549 regulates disc formation through the connecting cilium, a tubular conduit that physically links the outer segment to the photoreceptor cell body. Together, the aims address two molecular processes associated with outer-segment formation: membrane assembly and the cellular structure involved in disc formation. Spencer said the project seeks to unravel the molecular mechanisms underlying the function of PRCD and KIAA1549 in photoreceptor cells, with the stated hope that the work could contribute to the development of novel therapies for blinding retinal disease.

Spencer described the project as addressing a long-standing molecular mystery about vision: how outer segments are built and maintained. He said there is a complete lack of therapies for retinal diseases caused by defects in outer-segment formation and that a major barrier to developing treatments is an incomplete understanding of how the light-sensing structures are built. The R01 award therefore funds mechanistic investigation into a knowledge gap associated with inherited retinal disease. The announcement identifies no drug candidate, clinical trial or immediate therapeutic application resulting from the grant. Instead, its stated purpose is to define how the two genes’ proteins operate in photoreceptors, with potential therapeutic development presented as a hoped-for consequence of that work rather than an established outcome.

Subject of Research: Molecular mechanisms of photoreceptor outer-segment formation in inherited retinal disease

Article Title: Upstate researcher receives $2.3 million grant to study causes of blindness

Article References: Upstate researcher receives $2.3 million grant to study causes of blindness. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: photoreceptor outer segments, PRCD gene, KIAA1549 gene, retinitis pigmentosa, retinal degeneration, photoreceptor renewal, National Eye Institute, inherited blindness, cell biology, Upstate, researcher, receives

The technique, called nano-enhanced optical delivery (NOD), sidesteps the viral vectors that dominate current ophthalmic gene therapy. Adeno-associated viruses (AAVs), the workhorses of retinal gene transfer, carry a payload limit of roughly 4.7 kilobases, which restricts the delivery of large therapeutic genes and gene-editing tools such as CRISPR/Cas9. Viral vectors can also provoke inflammatory and immunological reactions, carry theoretical risks of genomic integration, and offer essentially no spatial control over where the therapeutic gene is expressed once administered. For diseases characterized by localized degeneration, such as geographic atrophy in advanced AMD, the inability to confine gene expression to the affected retinal regions is a significant drawback.

NOD addresses these limitations with a physical mechanism. The researchers functionalized gold nanorods with 5-kilodalton carboxyl-terminated polyethylene glycol to minimize nonspecific binding and prevent aggregation in physiological solutions. Transmission electron microscopy confirmed rod-shaped particles averaging approximately 120 nanometers in length and 25 nanometers in width, with a zeta potential of roughly −28 millivolts at pH 7. Ultraviolet–visible–near-infrared spectroscopy revealed a strong longitudinal plasmonic absorption band in the near-infrared region overlapping the 980-nanometer wavelength of the delivery laser. When irradiated at this wavelength, the nanorods convert optical energy into localized thermal energy, generating hotspots at the cell surface that transiently permeabilize the plasma membrane and allow extracellular plasmid DNA to enter the cell.

The therapeutic payload in this study was the MCO-020 plasmid, which encodes a multi-characteristic opsin designed to confer ambient-light sensitivity to retinal neurons. The expression cassette uses a CAG promoter driving the MCO-020 coding sequence, followed by a human growth hormone polyadenylation signal. The researchers first optimized delivery parameters in HEK293 cells, where immunostaining for the mCherry reporter protein revealed that transgene expression occurred only in cells exposed to laser irradiation. Cells incubated with plasmid and nanorods in the absence of laser exposure showed no detectable reporter expression, confirming that laser activation is required for plasmid entry. Increasing laser power from 10 to 20 milliwatts produced substantially stronger reporter fluorescence, and longer irradiation durations of 400 seconds yielded higher expression than 200 seconds. Adjacent non-irradiated areas within the same culture showed negligible signal, demonstrating that gene delivery was confined to the laser-targeted area.

To integrate this delivery mechanism with real-time anatomical guidance, the team combined a spectral-domain OCT subsystem centered at 840 nanometers with the 980-nanometer delivery laser through a fiber coupler, so that both beams share a common optical path toward the retina. The combined beam is collimated and directed toward the eye using micro-electromechanical system scanning mirrors and telescopic lenses. Fourier transformation of the detected interference spectrum produces depth-resolved structural images of the retina. Using en-face OCT imaging, the targeted region of interest is identified and marked on the imaging interface, and retinal features such as blood vessels serve as reference landmarks for tracking the position of the targeted region throughout the procedure. This feedback system enabled dynamic adjustment of the delivery beam to maintain precise alignment with the selected retinal area.

In vivo experiments were conducted in rd1 mice, which carry a mutation in the Pde6b gene encoding the β-subunit of rod photoreceptor phosphodiesterase. This mutation causes rapid degeneration of rod photoreceptors followed by secondary cone loss, producing severe visual impairment while preserving inner retinal neurons. The researchers injected 1 microliter of MCO-020 plasmid mixed with gold nanorods into the vitreous cavity of one eye, then positioned the animal under the OCT-guided delivery system approximately 2 hours later. A 980-nanometer continuous-wave near-infrared laser with an approximately 15-micrometer Gaussian focal spot was raster scanned over an approximately 1 × 1 millimeter retinal area, with laser powers of 10 to 30 milliwatts and total irradiation durations of 200 and 400 seconds evaluated.

OCT imaging performed immediately after laser irradiation revealed no detectable disruption of retinal structure or evidence of additional tissue damage within the targeted region. Retinal thickness measurements obtained from B-scan images showed no statistically significant differences between baseline and post-treatment time points. Confocal microscopy demonstrated robust MCO-020 expression, visualized through mCherry immunostaining, in retinal cells located within the laser-targeted region. Quantitative analysis showed that the number of MCO-expressing cells increased with increasing laser power, indicating that higher power produced greater transfection efficiency. Longitudinal quantification revealed persistent transgene expression for several months following delivery, with detectable expression remaining evident at the 12-month partial dataset point.

Electrophysiological recordings confirmed that the delivered opsin was functionally active. Visually evoked potential (VEP) recordings from the visual cortex showed dose-dependent increases following MCO-020 delivery, with treated mice exhibiting mean cortical responses of approximately 15 microvolts compared with roughly 6 microvolts in untreated controls, a statistically significant difference. In animals with strong retinal transgene expression, VEP responses were clearly detectable in the visual cortex, confirming successful transmission of visual signals through the retinal circuitry. These cortical responses persisted for up to 52 weeks following treatment, indicating long-term functional activity of the optogenetically modified retinal neurons. Intraocular pressure measurements remained comparable to control eyes throughout the study period, and retinal cell viability assays showed no significant differences between untreated controls, laser-only, nanorod-only, and combined treatment groups.

Biodistribution analysis performed at 12 months showed MCO-020 vector DNA below the limit of detection of 50 copies per nanogram in all evaluated non-target tissues, including brain, gonads, kidney, mesentery, spleen, heart, lungs, and liver. This finding supports limited systemic distribution following ocular delivery. In a separate focal photoreceptor injury model generated in wild-type mice using a 532-nanometer green laser, OCT en-face imaging confirmed localized retinal damage, and microfocal ERG recordings obtained from the damaged area showed markedly reduced responses prior to treatment. Following OCT-guided NOD delivery of MCO-020, significant recovery of focal ERG responses was observed within 1 week, demonstrating restoration of localized retinal activity in an experimentally defined region of injury.

The authors note several limitations. Direct retinal temperature measurements and nanorod-specific thermal modeling were not performed, so the reported exposure calculations characterize the delivered optical dose but do not establish the local temperature rise at the nanorod–cell interface. The full therapeutic window was not defined by escalation from ineffective exposure to the threshold for tissue injury, and published retinal laser-damage thresholds may not directly predict the NOD threshold because plasmonic nanorods locally enhance optical absorption and heat generation. The rd1 model represents inherited retinal degeneration rather than age-related macular degeneration and does not reproduce the chronic RPE dysfunction, inflammatory processes, or macular anatomy associated with human geographic atrophy. Nevertheless, the absence of detectable changes in retinal morphology, thickness, cell viability, intraocular pressure, and electrophysiological function supports tolerability within the tested operating range. The researchers suggest that the combination of OCT guidance and nano-enhanced optical delivery could serve as a platform for localized delivery of therapeutic genes, including gene-editing tools that exceed viral packaging limits, to retinal regions affected by degeneration.

Subject of Research: Optogenetic gene delivery

Article Title: Optical coherence tomography guided targeted non-viral optical delivery of opsin-encoding genes into the retina

Article References: Kim, S., Carlson, M., Batabyal, S., Dibas, A., & Mohanty, S. (2026). Optical coherence tomography guided targeted non-viral optical delivery of opsin-encoding genes into the retina. Frontiers in Pharmacology, 17, Article 1831339. https://doi.org/10.3389/fphar.2026.1831339

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1831339

Keywords: gene therapy, optogenetics, retinal degeneration, non-viral delivery, optical coherence tomography, gold nanorods, MCO-020, Optical, coherence, tomography, guided, targeted

Connexin 36 (Cx36) forms electrical synapses that allow direct cytoplasmic continuity between adjacent retinal neurons, enabling the rapid exchange of ions and small metabolites. In the outer retina, Cx36-containing gap junctions mediate rod-cone coupling and regulate visual signal integration, while in the inner retina, they contribute to electrical coupling between retinal ganglion cells and amacrine cells. These channels are essential for temporal precision in visual processing, enhancing signal-to-noise ratio and firing synchrony. However, under pathological conditions such as excitotoxicity, the same gap junctions that normally support healthy signal transmission can become conduits for the spread of toxic signals—including calcium overload and pro-apoptotic molecules—from injured neurons to their healthy neighbors.

The research team, led by Adrian Smędowski at the Medical University of Silesia in Katowice, Poland, used immortalized 661W murine photoreceptor cells transfected with GFP-tagged Cx36 to visualize the protein’s intracellular distribution under controlled stress conditions. The 661W cell line, derived from mouse cone photoreceptors, expresses cone-specific markers and retains light responsiveness through cGMP modulation, making it a physiologically relevant model for studying retinal photoreceptor biology. The researchers chose this model because it provides a more relevant retinal phenotype compared to other neuron-like cell lines, though they acknowledge that findings from an immortalized cell line must ultimately be validated in intact retinal tissue.

To probe the degradation pathways responsible for Cx36 turnover, the team employed two complementary pharmacological approaches. First, they used bafilomycin A1, a macrolide antibiotic that disrupts autophagic flux by blocking V-ATPase-dependent acidification of lysosomes and inhibiting autophagosome-lysosome fusion. Second, they exposed the cells to N-methyl-D-aspartate (NMDA) to induce excitotoxic stress, mimicking the glutamate-mediated overactivation that contributes to neuronal damage in retinal neurodegenerative diseases. By applying these interventions separately and in combination with Cx36 overexpression, the researchers could dissect the relative contributions of the autophagy-lysosome pathway and the ubiquitin-proteasome system (UPS) to connexin proteostasis.

The results revealed a striking pattern of proteostatic reorganization. Following bafilomycin A1 treatment, immunofluorescence analysis showed intracellular accumulation of the autophagy adaptor protein SQSTM1/p62, with signal intensities increasing approximately 1.5- to 2-fold compared to controls (n = 3, p < 0.05). Under normal conditions, p62 selectively binds polyubiquitinated protein aggregates and delivers them to autophagosomes via interaction with LC3, facilitating their degradation upon fusion with lysosomes. When this pathway is blocked, p62 itself accumulates because it can no longer be cleared. The researchers also observed a marked upregulation of PSMA1, a structural subunit of the 20S proteasome core particle, suggesting a potential compensatory shift toward proteasomal degradation when lysosomal clearance is compromised.

Perhaps most intriguingly, the team detected elevated levels of RAB11A, a small GTPase associated with the recycling endosome pathway. RAB11A controls the return of internalized receptors from recycling endosomes to the plasma membrane and contributes to vesicular trafficking processes underlying endosomal sorting. Its increased expression may reflect an adaptive cellular response to impaired protein degradation, potentially contributing to altered intracellular trafficking and redistribution of proteins—including Cx36—under stress conditions. Notably, the researchers did not observe changes in other endosomal markers such as EEA1, RAB5A, or RAB9A, suggesting that the recycling pathway specifically, rather than the broader endocytic machinery, is recruited in response to lysosomal blockade.

When the researchers turned to the excitotoxicity model, they found that NMDA treatment was associated with increased ubiquitin accumulation, particularly in Cx36-overexpressing cells. Ubiquitin serves as a molecular tag that marks damaged or misfolded proteins for degradation by the 26S proteasome through a cascade involving E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases. The enhanced ubiquitin signal in Cx36-expressing cells exposed to NMDA suggests that excitotoxic conditions compromise Cx36 stability and promote its ubiquitination, indicating enhanced proteostatic stress specifically in cells bearing higher loads of the gap junction protein. Interestingly, Cx36 immunoreactivity remained predominantly cytoplasmic with a punctate distribution pattern, and no major redistribution was observed following NMDA treatment.

The implications of these findings extend beyond basic cell biology. Previous studies have demonstrated that blocking gap junctions under excitotoxic or ischemic conditions can improve retinal ganglion cell survival by up to 70 percent, underscoring the critical role of intercellular communication in propagating neuronal injury. Genetic knockout studies have further shown that eliminating Cx36 significantly reduces retinal ganglion cell death under excitotoxic stress. The current work adds a new dimension to this understanding by suggesting that modulating Cx36 turnover or stabilization—rather than simply upregulating or downregulating its expression—may represent a more effective neuroprotective strategy. By targeting the proteostatic machinery that controls connexin degradation, it may be possible to fine-tune gap junction abundance and coupling strength in ways that preserve normal visual signal transmission while limiting the pathological spread of toxic signals.

The study’s authors are careful to note several important limitations. The immunofluorescence-based approach, while providing unique spatial resolution for assessing intracellular distribution, does not allow precise quantification of total protein expression. Definitive confirmation of impaired autophagic flux would require LC3-II turnover analysis, which was not performed in this study. Similarly, the observed PSMA1 upregulation suggests but does not prove functional proteasome involvement. The use of Cx36 overexpression itself may influence intracellular proteostasis, and the cytoplasmic distribution of the tagged protein likely reflects overexpression-driven accumulation within the endoplasmic reticulum or vesicular compartments rather than functional gap junction localization at the plasma membrane. Future work incorporating Western blotting, LC3-II flux assays, proteasome activity measurements, live-cell imaging, and validation in retinal explants or animal models will be essential to confirm and extend these preliminary observations.

Nevertheless, the study opens a compelling new avenue for investigating retinal neurodegeneration. Both glaucoma and age-related macular degeneration are characterized by progressive dysfunction of proteostatic mechanisms—whether through oxidative stress in the retinal pigment epithelium, mitochondrial dysfunction in retinal ganglion cells, or chronic neuroinflammation. If connexin proteostasis proves to be a modifiable node in these degenerative cascades, targeted pharmacological interventions aimed at specific degradation pathways could offer a precision approach to preserving vision. The researchers suggest that better understanding of these subcellular mechanisms will potentially allow the design of precisely targeted treatments in the future, transforming our approach to diseases that currently rob millions of people worldwide of their sight.

Subject of Research: Proteostatic regulation of the neuronal gap junction protein connexin 36 in photoreceptor cells under excitotoxic stress

Article Title: Gap junction protein connexin 36 proteostatic mechanisms in photoreceptor cells subjected to excitotoxic stress

Article References: Katan, M., Mróz, K., Pacwa, A., Lewin-Kowalik, J., & Smędowski, A. (2026). Gap junction protein connexin 36 proteostatic mechanisms in photoreceptor cells subjected to excitotoxic stress. Acta Biochimica Polonica, 73, Article 16091. https://doi.org/10.3389/abp.2026.16091

Image Credits: AI Generated

DOI: 10.3389/abp.2026.16091

Keywords: connexin 36, gap junctions, photoreceptors, excitotoxicity, autophagy, ubiquitin-proteasome system, retinal degeneration, glaucoma, age-related macular degeneration, p62/SQSTM1, RAB11A, proteostasis

Researchers at the State University of Campinas in Brazil, working with collaborators in Hungary, Switzerland, France and São Paulo, turned to the Townes HbSS mouse, a humanized model of sickle cell anemia in which the animals carry the same single-point mutation in the beta-globin gene that defines the human disease. That mutation, a substitution of valine for glutamic acid at the sixth codon, causes hemoglobin S to polymerize when deoxygenated, deforming red cells into their characteristic crescent shape. The resulting rigidity and membrane alterations drive hemolysis, endothelial dysfunction, vaso-occlusion and ischemia throughout the body, and the retina, with its exceptionally high metabolic demand, is particularly vulnerable to the consequences.

To confirm that the model faithfully reproduced the human condition, the team first characterized the animals’ blood. Compared with C57BL/6J controls, the Townes HbSS mice showed reductions of roughly 58 percent in erythrocyte count, 52 percent in hematocrit and 46 percent in hemoglobin concentration, alongside dramatic elevations in reticulocytes and white blood cells. Markers of hemolysis told a similar story: total, direct and indirect bilirubin levels were all massively increased, consistent with the ongoing destruction of red cells that characterizes sickle cell anemia. These hematological and metabolic signatures confirmed that the experimental group carried the disease phenotype before any retinal analysis began.

The researchers then probed retinal function using electroretinography, a technique that measures the electrical potentials generated between the cornea and the retina in response to flashes of light of varying intensity. Under dark-adapted conditions, which isolate rod photoreceptor activity, the sickle cell mice produced a-wave amplitudes significantly smaller than controls at the highest light intensity tested, and their implicit times were shortened at an intermediate flash strength. Under light-adapted conditions, which emphasize cone and bipolar cell responses, the b-wave implicit time was prolonged in the diseased animals, indicating a delayed signal in the bipolar cell layer. Perhaps most strikingly, the oscillatory potentials, small rhythmic wavelets superimposed on the b-wave that are thought to reflect inner retinal amacrine cell activity, were reduced in amplitude at maximum light intensity, hinting at early damage to the inner retina before gross structural changes appear.

Histological examination of stained retinal sections reinforced this picture of degeneration. Both the sickle cell mice and the aged controls showed some disorganization of the outer nuclear layer, where photoreceptor cell bodies reside, but the Townes HbSS animals also displayed discrete alterations in the inner nuclear layer, suggesting a pathophysiological process distinct from simple aging. Blood vessels were additionally observed within the ganglion cell layer of the sickle cell retinas, a finding the authors interpret as consistent with the vascular remodeling that accompanies the disease. Because the control strain is known to undergo gradual photoreceptor degeneration beginning around six months of age, the team attributes the inner retinal changes in the sickle cell mice specifically to the vaso-occlusion and hypoxia of the disease rather than to time alone.

The centerpiece of the study, however, is the proteomic analysis. Using label-free quantification on an LTQ Orbitrap Velos mass spectrometer coupled to nanoflow liquid chromatography, the researchers mapped the retinal proteome across pooled samples from five sickle cell mice and seven controls. The analysis identified 2,248 proteins in total, of which 163 were detected exclusively in control retinas and 43 only in the sickle cell group. After applying a nominal significance threshold, 268 proteins emerged as differentially expressed: 63 upregulated and 205 downregulated in the diseased retinas. While no individual protein survived correction for false discovery rate, the pattern of change was far from random, and functional enrichment analysis revealed a coherent molecular story.

Among the downregulated proteins, the most heavily enriched pathways were phototransduction, the citric acid cycle and oxidative phosphorylation, the mitochondrial machinery that generates most of the cell’s ATP. Among the upregulated proteins, the enriched pathways included glycolysis, gluconeogenesis and signaling through hypoxia-inducible factor 1, the master transcriptional regulator of the cellular response to low oxygen. This reciprocal pattern, a collapse of oxygen-dependent energy production paired with an activation of hypoxia-adaptive programs, mirrors what has been observed in other proliferative retinopathies such as retinopathy of prematurity, where independent work has shown that mitochondrial respiration declines at the peak of neovascularization and that supplying metabolic substrates can suppress pathological angiogenesis.

Within the phototransduction pathway, several proteins stood out. The Pde6 family, comprising the alpha, beta and gamma subunits of rod phosphodiesterase, was downregulated, as were Cnga1, the alpha subunit of the cyclic nucleotide-gated channel that carries sodium and calcium into the photoreceptor outer segment, and Slc24a1, a sodium-calcium-potassium exchanger that regulates calcium clearance and photoreceptor recovery after light exposure. Mutations in these same genes are known causes of retinitis pigmentosa and congenital stationary night blindness in humans, disorders characterized by progressive photoreceptor degeneration. To verify that the protein-level findings reflected genuine transcriptional changes, the researchers performed quantitative reverse transcription PCR on selected targets, confirming that both Cnga1 and Slc24a1 messenger RNA were also reduced in the sickle cell retinas, in agreement with the proteomic data.

The convergence of proteomic and transcriptomic evidence on the phototransduction cascade carries particular weight because it suggests that the molecular machinery for converting light into neural signals is being dismantled early in the disease process, before the morphological and functional deficits become pronounced. In a single-cell RNA sequencing study of a retinitis pigmentosa model, downregulation of Pde6g, Cnga1 and Slc24a1 was interpreted as a signature of early rod degeneration that precedes clinical manifestations. The sickle cell retina appears to be following a similar trajectory, driven not by genetic mutation of the photoreceptors themselves but by the hypoxic and ischemic environment created by vaso-occlusion in the microvasculature that supplies them.

The clinical implications are sobering. Current treatments for proliferative sickle cell retinopathy, including laser photocoagulation, intravitreal anti-VEGF injections and vitrectomy for advanced complications, are borrowed from other proliferative retinopathies without dedicated prospective trials in the sickle cell context. While anti-VEGF therapy has shown benefit in regressing seafan vessels and improving vision, recent work in a mouse model of retinal vascular disease found that chronic VEGF inhibition failed to rescue the expression of phototransduction-related genes or prevent photoreceptor loss, raising the possibility that vascular-targeted approaches alone may not address the full spectrum of retinal damage in sickle cell disease. By identifying the metabolic and phototransduction pathways that are compromised before overt structural breakdown, this proteomic study provides a molecular foundation for developing biomarkers that could detect sickle cell retinopathy earlier and for designing mechanism-based therapies that protect photoreceptors directly rather than merely pruning abnormal vessels. The authors acknowledge limitations, including the use of the C57BL/6J strain as controls rather than the ideal Townes HbAA comparator and the absence of retinal flat-mount analysis for angiogenesis quantification, but the molecular landscape they have charted offers a starting point for a field that has long lacked one.

Subject of Research: Proteomic analysis of retinal molecular pathways in a humanized mouse model of sickle cell retinopathy

Article Title: Sickle cell retinopathy molecular investigation through proteomic analysis of Townes HbSS mice retinas

Article References: de Castro, J. N. P., Monte, A. R. C., de Oliveira, A. C. R., Acacio, J. D., Rodrigues, T. A. R., Barboni, M. T. S., Liber, A. M. P., Bonci, D. M. O., Ventura, D. F., Costa, F. F., Camargo, A. C. L., & de Melo, M. B. (2026). Sickle cell retinopathy molecular investigation through proteomic analysis of Townes HbSS mice retinas. Experimental Biology and Medicine, 251, Article 11228. https://doi.org/10.3389/ebm.2026.11228

Image Credits: AI Generated

DOI: 10.3389/ebm.2026.11228

Keywords: sickle cell retinopathy, sickle cell disease, proteomics, Townes HbSS mice, phototransduction, oxidative phosphorylation, hypoxia, retinal degeneration, anti-VEGF, electroretinography, biomarkers, retina

Retinitis pigmentosa is a group of inherited retinal degenerations that affects more than 1.5 million people worldwide. The disease progressively destroys the retina’s photoreceptors, the rods and cones that normally capture light and convert it into electrical signals for the brain. Patients typically first notice difficulty seeing at night, followed by a narrowing of peripheral vision that worsens over years, ultimately leading to severe vision loss or blindness. Because the retina is part of the central nervous system, its capacity for self-repair is extremely limited, and once photoreceptors are lost they are not naturally replaced.

One of the central obstacles to treating the disease is its sheer genetic diversity. Retinitis pigmentosa can arise from mutations in any one of more than 100 distinct genes, which makes a mutation-by-mutation strategy impractical for most patients. Gene therapies that correct specific defects have succeeded for other blinding conditions, but building and validating a separate treatment for every causative gene is proving tremendously difficult and costly. The Pittsburgh-led team, under the direction of José-Alain Sahel, chair of ophthalmology at Pitt and director of the UPMC Vision Institute, pursued a fundamentally different logic: rather than fixing the underlying mutation, the therapy aims to make surviving retinal cells light-sensitive again, regardless of which gene caused the degeneration.

The technical approach relies on optogenetics, in which cells are genetically altered to produce light-sensing proteins borrowed from other organisms. In this trial, the researchers delivered a gene encoding a protein called ChrimsonR into surviving retinal ganglion cells through a single injection into the eye. Retinal ganglion cells are the output neurons of the retina; in a healthy eye they relay signals from photoreceptors to the brain, and in advanced retinitis pigmentosa many of them remain viable even after the light-sensing cells above them have died. By equipping these surviving cells with an engineered light-sensitive protein, the therapy effectively converts the retina’s output neurons into a substitute photoreceptor layer.

ChrimsonR alone is not enough, however. The protein responds to specific wavelengths of amber-red light, and ordinary ambient illumination is not structured in a way the modified cells can interpret usefully. To bridge that gap, participants wear specialized goggles with a built-in camera that captures the visual scene and sends the information to a portable processor. The processor converts the image into patterns of light at wavelengths designed to activate ChrimsonR, and a projector inside the goggles projects those patterns back onto the retina. The system can, for example, transform the image of a hand into a simplified pattern of light that stimulates the treated cells, allowing the brain to receive visual information through a completely rewired pathway.

On safety, the early-stage trial delivered encouraging results. Most eye-related side effects were mild or moderate, consisting mainly of temporary inflammation and short-lived increases in pressure inside the eye. No findings reported in the release suggested the therapy itself caused lasting harm, an important benchmark for a treatment that involves permanently introducing a new light-sensing protein into neural tissue. The researchers emphasize that this was a small, early-stage study, and that the treatment did not restore normal vision or the ability to read. Even so, some participants became better able to detect when an object was present, determine where it was located, and reach toward it accurately while using the goggles, functional abilities that can translate into greater independence in daily life.

The study went beyond behavioral testing to ask whether the new visual signals were actually reaching the brain. Using electroencephalography, a team led by Marlene Behrmann, professor of ophthalmology at Pitt, found evidence that visual signals reached and were processed by the visual cortex when participants viewed objects. That finding is scientifically striking, because it suggests that in people with profound, long-standing vision loss, the brain’s visual processing machinery remains intact and capable of interpreting input delivered through an entirely novel channel. Four participants showed consistent improvements across multiple real-world visual tasks over months to years of testing, indicating that the gains were not fleeting artifacts of a single laboratory session.

Sahel noted that the results demonstrate the visual system retains a remarkable capacity to process new information even after profound vision loss. He also pointed to the approach’s broader potential: because the strategy targets surviving retinal ganglion cells rather than any specific mutation, it could in principle help patients with other blinding diseases in which light-sensing cells have been lost but ganglion cells remain viable, a group that currently has few or no treatment options. That mutation-agnostic design is what distinguishes optogenetic therapy from the growing but still narrow portfolio of gene-specific treatments.

The new findings build directly on a landmark 2021 study published in Nature Medicine, which reported the first partial recovery of visual function in a blind patient following optogenetic therapy, the first clinical application of optogenetics in medicine. That work, carried out with longtime collaborator Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel, who is also a corresponding author of the current study, earned the two researchers the António Champalimaud Vision Award, the largest prize in the field, last month. The current trial was conducted as part of the PIONEER clinical study with support from GenSight Biologics, and included collaborators from Sorbonne Université, Institut de la Vision, and L’Hôpital Fondation Adolphe de Rothschild in Paris, the Institute of Molecular and Clinical Ophthalmology Basel and University of Basel in Switzerland, Streetlab in Paris, and Moorfields Eye Hospital in London.

The optogenetic program is one of several complementary strategies the Pittsburgh-led team is pursuing for end-stage retinal disease. Last year, Sahel was senior author of a New England Journal of Medicine paper describing vision restoration using an implanted prosthetic device, known as PRIMA, in patients with end-stage age-related macular degeneration. That technology has since received European Union authorization to be marketed for clinical use in many European countries. Together, the two approaches illustrate a shifting landscape in which blindness once considered irreversible is being reclassified as a engineering problem: if light-sensing cells are gone, the task becomes finding surviving neural tissue that can be repurposed to carry visual signals, whether by genetically reprogramming ganglion cells or by implanting a photovoltaic prosthetic. For the retinitis pigmentosa community, the new trial offers the strongest evidence yet that such repurposing can work safely in humans, while underscoring how much work remains before the therapy could move from a small trial toward approved, widely available treatment.

Subject of Research: Optogenetic gene therapy for restoring visual function in advanced retinitis pigmentosa

Article Title: Optogenetic therapy safe, shows signs of vision restoration in patients with advanced retinitis pigmentosa, according to international study led by Pitt scientists

Article References: Optogenetic therapy safe, shows signs of vision restoration in patients with advanced retinitis pigmentosa, according to international study led by Pitt scientists. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: optogenetics, retinitis pigmentosa, gene therapy, retinal ganglion cells, ChrimsonR, visual prosthesis, New England Journal of Medicine, University of Pittsburgh, vision restoration, clinical trial, retinal degeneration, visual cortex

The team, led by first authors Dogan Can Kirman and Ashley A. Rowe under the senior guidance of Katherine J. Wert and Rafael L. Ufret-Vincenty, generated mice lacking Herc3 using CRISPR-Cas9 genome editing. Herc3 encodes an E3 ubiquitin ligase, a molecular tagger that marks misfolded or damaged proteins for destruction by the proteasome, the cell’s waste-disposal complex. Without it, protein quality control collapses, and cells — especially metabolically demanding neurons like photoreceptors — accumulate toxic debris. The researchers had previously noticed a hint that female mutants fared worse; this study was designed to test that suspicion rigorously, tracking retinal anatomy, function, and gene expression in male and female animals as they aged.

The structural evidence was unambiguous. By 15 months of age, optical coherence tomography, a non-invasive imaging technique that cross-sections the living retina, revealed significantly accelerated thinning of the outer retina in females compared with males. Histological examination confirmed the finding, showing that the outer nuclear layer — the densely packed band containing the cell bodies of rod and cone photoreceptors — was markedly thinner in females, with a statistical significance of P = 0.0013. In plain terms, the females were losing the very cells that capture light. Fundus photography, which images the interior surface of the eye, told a parallel story: aging females accumulated significantly more bright spots on the retina, a feature the authors link to subretinal microglia, the resident immune cells of the nervous system. Greater spot accumulation, statistically significant at 14 to 16 months, pointed to amplified neuroimmune activation in female eyes.

Function tracked structure. Electroretinography, which measures the electrical responses of retinal cells to flashes of light under dark-adapted (scotopic) conditions, showed significantly weakened responses in female mutants at 12 and 16 months of age. Because scotopic responses primarily reflect rod photoreceptor activity, the results indicate that the females’ dim-light vision was deteriorating measurably faster than the males’. Together, the imaging, histology, and electrophysiology establish that female sex is associated with accelerated degeneration across every level of analysis — from molecules to tissue architecture to behaviorally relevant visual function.

The most striking insights, however, came from the molecular level. The team performed bulk RNA sequencing on neuroretinas from young, pre-degenerative mice, just 8 to 10 weeks old, when the retina still looks structurally normal. Even at this early stage, female mutants carried a distinct transcriptional fingerprint: 143 genes were differentially expressed relative to males, with 90 downregulated and 53 upregulated. The upregulated networks were dominated by mitochondrial energy metabolism, protein translation, RNA processing, and genome maintenance — pathways that, when cranked up in a young tissue, signal compensatory stress rather than vigor. The female retinas were essentially working overtime, burning extra metabolic and proteostatic resources to keep pace with the damage caused by Herc3 loss.

Meanwhile, the downregulated genes told the complementary half of the story. Pathways governing extracellular matrix organization, structural tissue development, lipid and hormone metabolism, and baseline inflammatory regulation were quieter in the young female retinas. The extracellular matrix provides the scaffolding that holds retinal cells in place and supports their survival, so its early suppression suggests that female tissue maintenance and structural integrity were already compromised before any thinning could be seen. In the authors’ interpretation, the young female retina exists in a more vulnerable state: higher metabolic and proteostatic demand running on a weaker structural foundation. Over time, that chronic imbalance culminates in homeostatic breakdown.

The late-stage molecular profile confirmed this trajectory. In aging mutants at 14 to 16 months, degenerating female retinas showed heightened expression of neuroinflammatory and microglial activation markers, including Aif1, Cd68, Itgam, Ccl5, and Il23a. They also displayed signs of proteostatic failure, with elevated Casp4, Tnfrsf10b, and Tnfrsf1a — genes associated with inflammatory cell-death pathways — alongside disruption of autophagy, the cell’s recycling system, marked by changes in Atg12. Perhaps most tellingly, the females lost expression of Nrl, a master transcription factor that defines photoreceptor identity. The loss of a cell’s core identity program is a hallmark of terminal degeneration, indicating that female photoreceptors were not merely stressed but actively dying and dedifferentiating.

What drives this female-specific vulnerability? The researchers turned to sex hormones for an answer. They compared ovariectomized Herc3-deficient females — animals whose ovaries had been removed, eliminating the primary source of estrogen and other ovarian hormones — with intact female mutants. The transcriptomic differences between these groups supported a role for female sex hormones in heightening susceptibility to retinal degeneration and microglial activation. This finding is provocative because it inverts a common assumption: rather than protecting the retina, ovarian hormones appear to amplify the damage when protein quality control fails, at least in this model. The authors caution that the data establish an association and a role for hormones in susceptibility, and the precise hormonal mechanisms remain to be worked out.

The broader significance of the study extends well beyond ophthalmology. Retinal degeneration is increasingly studied as a window into neurodegeneration generally, because the retina is accessible, imageable, and mechanistically akin to brain tissue. Many neurodegenerative and retinal diseases — from Alzheimer’s and Parkinson’s to age-related macular degeneration — show sex-biased prevalence or severity, yet the biological reasons remain poorly understood, and females have historically been understudied in neuroscience research. By establishing Herc3-deficient mice as a robust model of sex-dependent retinal neurodegeneration, the UT Southwestern team has created a platform for dissecting those mechanisms and, critically, for testing interventions at the right stage of disease in the right sex.

The study also carries a practical message about therapeutic timing. Because the female-specific molecular signature appears in young, pre-degenerative retinas, it defines an early, phase-specific therapeutic window — a period when boosting tissue maintenance, easing metabolic load, or supporting proteostasis might prevent the later cascade of inflammation and cell death. Conversely, the late-stage profile of neuroinflammation, autophagic failure, and photoreceptor loss suggests that once disease is established, different targets would be needed. The authors argue that distinct, sex-specific therapeutic windows should be developed for male and female patients, a conclusion that aligns with a growing movement in precision medicine to treat biological sex as a fundamental variable rather than a nuisance factor. For the millions of people — disproportionately women in many retinal diseases — facing progressive vision loss, the finding that the female retina carries a measurable molecular vulnerability from early life is both a warning and a roadmap: the damage begins long before symptoms, and that hidden early phase may be exactly where treatment can succeed.

Subject of Research: Sex-dependent retinal neurodegeneration in Herc3-deficient mice

Article Title: Female sex accelerates retinal neurodegeneration in Herc3-deficient mice

Article References: Kirman, D. C., Rowe, A. A., Kumar, A., Xing, C., Turpin, E. R., Ulker-Yilmazer, G., Aredo, B., Wert, K. J., & Ufret-Vincenty, R. L. (2026). Female sex accelerates retinal neurodegeneration in Herc3-deficient mice. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00999-2

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00999-2

Keywords: Herc3, retinal degeneration, sexual dimorphism, ubiquitin-proteasome system, neuroinflammation, microglia, photoreceptors, sex hormones, CRISPR-Cas9, RNA sequencing, electroretinography, ovariectomy

The study, published in the Journal of Translational Medicine, describes how the researchers retooled the AAV5 capsid using rapid directed evolution. Their strategy centered on variable region VIII of the viral capsid protein, a surface-exposed loop that governs how the virus engages cellular receptors. At residue Q574 within this region, they inserted libraries of random heptapeptides, seven-amino-acid sequences that collectively presented an enormous diversity of receptor-binding profiles. Each randomized capsid was packaged with its own encoding genome, so that the viral particles effectively carried the blueprint of their own success. The library was then subjected to iterative selection on 661W cells, a well-established mouse photoreceptor-derived cell line, allowing only those variants that entered these cells efficiently to amplify through successive rounds.

This selection scheme is a classic example of artificial Darwinism applied to a gene therapy vector. Rather than rationally designing a single capsid modification and hoping it improves tropism, the team let the biology choose. Millions of capsid variants competed for entry into photoreceptor-like cells, and the fittest clones were recovered, re-amplified, and challenged again. After several rounds, one variant emerged as the clear winner and was designated AAV5-AlyT. The name reflects its tropism for the outer retinal layers, and the variant carries a heptapeptide insertion at the Q574 position that presumably alters the capsid’s interaction with receptors on the inner limiting membrane and on photoreceptor cells themselves, the two principal barriers that natural AAV5 must overcome after intravitreal delivery.

In vitro comparisons confirmed that AAV5-AlyT transduced 661W cells far more efficiently than its parental AAV5 scaffold. The critical question, however, was whether that cellular advantage would translate into living eyes, where the vitreous, the inner limiting membrane, and the layered architecture of the retina impose constraints that cell culture cannot reproduce. In mice, a single intravitreal injection of AAV5-AlyT carrying a reporter transgene produced robust gene expression concentrated in the outer retina, the compartment containing photoreceptor inner and outer segments. The expression was not a transient burst; it persisted for more than six months after the single injection, an essential property for any therapy aimed at chronic degenerative diseases in which the treated cells must be supported for years.

The vector’s performance extended beyond mice. In rabbits, whose eyes are larger and anatomically closer to the human eye in several respects, AAV5-AlyT achieved efficient transduction across retinal layers after intravitreal delivery. Cross-layer transduction is a notable feature, because it suggests the capsid can penetrate the inner limiting membrane and then distribute genetic cargo to cells in multiple retinal strata rather than being confined to a narrow band. For translational purposes, this matters enormously: rabbit and non-human primate eyes are the standard large-animal models used to de-risk retinal gene therapy before human trials, and a vector that fails to scale from mouse to larger eyes rarely survives the development pipeline.

Having established delivery efficiency, the researchers tested whether AAV5-AlyT could actually treat disease. They chose two complementary models of retinal degeneration. The first was the ABCA4 knockout mouse, a model of Stargardt disease, an inherited macular dystrophy caused by mutations in the ABCA4 transporter gene that lead to toxic lipofuscin accumulation in photoreceptors and the retinal pigment epithelium. The second was light-induced retinal degeneration, a widely used model that recapitulates aspects of dry age-related macular degeneration, in which excessive light exposure triggers photoreceptor death and inflammatory degeneration. In both models, the therapeutic cargo was not a replacement gene but the complement regulator Crry, a mouse analogue of human complement regulatory proteins that dampens the cascade of complement activation driving tissue damage.

The results were striking. AAV5-AlyT-mediated delivery of Crry markedly rescued visual function in both disease models, as measured by electroretinography, the standard electrophysiological test of retinal responsiveness to light. Immunofluorescence and histological analyses showed that the treatment suppressed pathological complement activation and reduced damage to the retinal pigment epithelium, the support layer whose dysfunction is central to both Stargardt disease and dry AMD. These findings position the vector not merely as a delivery tool but as a validated platform for anti-inflammatory and neuroprotective gene therapy in the outer retina, where complement dysregulation is increasingly recognized as a key driver of degeneration.

One of the most clinically consequential findings concerns pre-existing immunity. A significant fraction of the human population carries neutralizing antibodies against common AAV serotypes, generated by prior natural infection, and these antibodies can neutralize therapeutic vectors before they reach their target cells, rendering treatment ineffective or forcing exclusion of patients from trials. The team screened 300 human serum samples for neutralizing activity against AAV5 and against the engineered AAV5-AlyT. The engineered variant showed a 34.9 percent lower rate of pre-existing neutralizing antibody response than parental AAV5. The heptapeptide insertion, while enhancing retinal tropism, apparently also perturbed an antibody epitope on the capsid surface, a serendipitous but valuable outcome that could broaden the eligible patient population for future therapies built on this capsid.

The technical achievement rests on a few principles worth underscoring. Directed evolution of AAV capsids has produced several notable vectors in recent years, but the field has struggled to find variants that combine outer retinal tropism with the practicality of intravitreal delivery. The Q574 locus in variable region VIII proved to be a productive engineering site, likely because it sits within a capsid region that influences both receptor binding and antibody recognition. The iterative selection on a photoreceptor cell line provided a clean, high-throughput fitness landscape, and the two-animal-species validation, followed by therapeutic proof of concept in two distinct degeneration models, gives the work an unusually complete translational arc for a single study.

Caveats remain, as they always do at this stage. The efficacy data come from mouse and rabbit models, and the human eye presents additional barriers, including a thicker inner limiting membrane and a much larger vitreous volume, that will require testing in larger animals and eventually in clinical trials. The Crry protein used as therapeutic cargo is mouse-specific, so human applications would require an equivalent human complement regulator. The authors also note a patent application related to the capsid, reflecting the commercial interest that engineered AAV vectors typically attract. Even so, AAV5-AlyT addresses the central logistical obstacle that has limited retinal gene therapy to specialized surgical centers: the need for subretinal injection. A vector that reaches photoreceptors through an intravitreal shot, sustains expression for over six months, evades a meaningful fraction of pre-existing neutralizing antibodies, and has already demonstrated functional rescue in models of both inherited and age-related retinal degeneration represents a substantial step toward making outer retinal gene therapy as routine as the injections ophthalmologists deliver every day.

Subject of Research: Directed evolution of an adeno-associated virus capsid for outer retinal gene delivery

Article Title: An engineered AAV variant with high-efficiency outer retinal tropism for gene delivery

Article References: Li, Y., Zhao, Z., Chen, Y., Zai, X., Chen, Z., Zhang, J., Zhang, Z., Wang, B., Song, X., Long, J., Wu, S., & Hou, L. (2026). An engineered AAV variant with high-efficiency outer retinal tropism for gene delivery. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09022-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09022-z

Keywords: adeno-associated virus, directed evolution, gene therapy, retinal degeneration, intravitreal injection, photoreceptors, Stargardt disease, age-related macular degeneration, viral vectors, complement cascade, neutralizing antibodies, AAV5-AlyT

Inherited retinal dystrophies are a leading cause of irreversible blindness worldwide, and retinitis pigmentosa, the most common form, affects an estimated 2.5 million people. More than 100 causative genes have been identified, yet between 30 and 50 percent of cases still lack a genetic diagnosis, and the observation of incomplete penetrance hints that factors beyond DNA sequence are at work. Epigenetic mechanisms, which modulate gene expression without altering the genome, have increasingly come into focus in ocular disease. Among these, m6A stands out as the most abundant internal modification in eukaryotic messenger RNA, deposited by writer enzymes, removed by erasers such as FTO and ALKBH5, and interpreted by reader proteins that influence splicing, export, stability, and translation.

METTL16 is a relative newcomer to the m6A field. Unlike the well-known METTL3/METTL14 complex, it recognizes a specific motif, UACAGARAA, within structured RNA contexts, and its validated substrates include MAT2A mRNA, which it regulates to maintain cellular levels of the universal methyl donor S-adenosylmethionine, and U6 snRNA, a small nuclear RNA at the heart of the splicing machinery. METTL16 methylates U6 at position A43 within the ACAGAGA sequence that base-pairs with the 5′ splice site of introns during pre-mRNA splicing. Work in fission yeast, roundworms, plants, and human cells has shown that losing this modification impairs 5′ splice site recognition. Intriguingly, dominant mutations in U6 snRNA have recently been linked to autosomal dominant retinitis pigmentosa, and those variants cluster in regions that contact spliceosome components such as PRPF3, PRPF8, and PRPF31, proteins that are themselves mutated in RP.

To probe METTL16’s role in the retina, the team, led by Jiangbo Ren, Wenjing Liu, and colleagues, generated rod-specific Mettl16 knockout mice by crossing Mettl16-floxed animals with RHO-Cre mice, in which the recombinase is active only in rods. The resulting RKO mice showed efficient excision of the targeted exon and a marked reduction of METTL16 protein in the retina. Single-cell RNA sequencing data from the Human Protein Atlas had already indicated that METTL16 is broadly expressed across retinal cell types, with notable enrichment in rods, making the knockout strategy well suited to testing its function in the cells most vulnerable to retinitis pigmentosa.

The physiological consequences were swift and measurable. Electroretinograms recorded at one month of age revealed that scotopic responses, which reflect rod function, were severely blunted: a-wave and b-wave amplitudes were reduced by roughly 54 and 55 percent, respectively, compared with littermate controls. Cone-mediated photopic responses, by contrast, were largely preserved at this stage, pointing to a rod-first pattern of degeneration. Behavioral assays corroborated the electrophysiology. In a light-dark box test, RKO mice spent only about 39 percent of their time and traveled about 42 percent of their distance in the dark chamber, unlike control mice, which normally prefer darkness. Their optomotor response, a reflexive head movement that tracks rotating visual gratings, dropped to 1.56, well below the values of 2.0 or higher seen in controls.

Under the microscope, the story continued. At postnatal day 20, retinal architecture looked normal, but by day 30 the outer nuclear layer and outer segments of RKO retinas were visibly thinning, and by day 40 the outer nuclear layer had lost roughly 40 percent of its thickness relative to controls. Immunofluorescence showed that key outer segment proteins, including rhodopsin, PRPH2, GRK1, PDE6B, and CNGA1, were markedly reduced in abundance even though their localization within the photoreceptor was not disrupted. Signs of degenerative stress were everywhere: Müller glia became reactive, microglia adopted an amoeboid morphology and invaded the outer nuclear layer, and TUNEL staining detected apoptotic nuclei among the photoreceptors. Cones, meanwhile, showed only delayed involvement, with reduced M-opsin-positive cells appearing by day 40.

To trace the molecular roots of this collapse, the researchers integrated RNA sequencing with quantitative proteomics on one-month-old retinas. Among the genes concordantly downregulated at both the transcript and protein levels, Gene Ontology and KEGG analyses pointed squarely at photoreceptor development, photoreceptor cilia, inner and outer segments, visual perception, and the phototransduction cascade. Five established retinitis pigmentosa genes emerged from this analysis: Tulp1, Cnga1, Pde6g, Crb1, and Prcd. Four of them showed significant differential expression at both levels after correction for multiple testing, and the reductions were confirmed by RT-qPCR and Western blotting. The metabolic arm of the analysis revealed perturbations in the S-adenosylmethionine pathway as well, with Mat2a mRNA, a direct METTL16 substrate, reduced in knockout retinas, and Csad, a key enzyme of taurine biosynthesis, markedly decreased.

The mechanistic core of the paper lies in splicing. Using a single-base elongation and ligation-based qPCR assay called SELECT on purified U6 snRNA, the team confirmed that m6A at position A43 was reduced in knockout retinas. Transcriptome-wide analysis with rMATS then revealed extensive alternative splicing changes, with skipped exons as the predominant event class. Sequence analysis of affected 5′ splice sites showed a telling pattern: sites whose usage decreased in knockout retinas were enriched for adenosine at the +4 position, the very nucleotide engaged by methylated U6, and carried an RAG motif across the U6-interacting positions, whereas sites with increased usage favored stronger U5 snRNA base pairing and non-adenine nucleotides at +4. Crucially, aberrant splicing was already detectable at postnatal day 20, before any overt cell loss. Both Tulp1 and Pde6g, two established retinal dystrophy genes, showed increased exon skipping, and the affected donor sites shared the conserved //GURAG motif previously implicated in METTL16 loss in plants and worms. MeRIP-seq showed no change in m6A enrichment on the Tulp1 and Pde6g transcripts themselves, consistent with a U6-dependent mechanism rather than direct methylation of the mRNAs. The Tulp1 exon 4-skipped transcript is predicted to encode an in-frame deletion of 51 amino acids, and immunostaining revealed disrupted ribbon synapse architecture in knockout retinas, echoing the synaptic defects known from Tulp1 knockout mice.

The study also documented METTL16’s influence beyond the nucleus. MeRIP-seq identified Tor1b and Nlgn2 as candidate direct m6A targets, with reduced methylation in their 3′ untranslated regions and reduced expression in knockout retinas; luciferase reporter assays showed that wild-type METTL16 enhanced reporters bearing the wild-type 3′ UTRs but not motif-mutated versions, and a catalytic-domain-deficient METTL16 mutant failed to do so. In photoreceptor-derived 661W cells, loss of METTL16 accelerated the decay of both transcripts, indicating effects on mRNA stability. Meanwhile, immunoprecipitation coupled with mass spectrometry revealed that retinal METTL16 associates with translation factors including PURA, PABPC1, and EIF3B, and with the splicing factors SF3B1 and SF3B3. SUnSET assays and polysome profiling showed that Mettl16 knockdown reduced global translation efficiency in 661W cells, and polysome analysis confirmed diminished translational efficiency of phototransduction genes such as Cep164, Rpgr, Prph2, and Cnga1, whose mRNA levels were unchanged even as their proteins declined.

The authors are careful to note the limitations: most molecular analyses used bulk retinal tissue, which can blur cell-type-specific effects and mix primary METTL16-dependent events with secondary degenerative changes, and the mechanistic work relied on the 661W cell line because mature rods are difficult to manipulate in vitro. Catalytically dead rescue experiments and ribosome profiling will be needed to determine whether the translational role depends on methyltransferase activity. Even so, the picture that emerges is striking. METTL16, working in both the nucleus and the cytoplasm, appears to safeguard photoreceptors on at least three fronts: by methylating U6 snRNA to preserve splicing fidelity in dystrophy genes, by stabilizing specific m6A-marked transcripts, and by supporting the translation of the proteins that build the light-sensing machinery. Given that mutations in U6 snRNA and multiple spliceosome components cause retinitis pigmentosa in humans, the study suggests that RNA processing defects may be a broader and previously underappreciated theme in photoreceptor disease, one that could eventually inform diagnostic and therapeutic strategies for the many patients whose blindness still has no genetic explanation.

Subject of Research: The role of the m6A methyltransferase METTL16 in photoreceptor survival and retinal degeneration

Article Title: METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation

Article References: Ren, J., Liu, W., Zou, R., Sun, K., Yang, M., Zhu, X., & Yang, Z. (2026). METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.012

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.012

Keywords: METTL16, m6A, photoreceptors, retinitis pigmentosa, U6 snRNA, alternative splicing, RNA methylation, retinal degeneration, translation regulation, Tulp1, Pde6g, epitranscriptomics

SCA7 belongs to a family of neurological diseases caused by expanded tracts of the three-letter DNA sequence CAG embedded within a gene. In this case the culprit is the ATXN7 gene on chromosome 3, which normally encodes a subunit of a protein complex called SAGA that regulates the transcription of thousands of other genes. When the CAG tract expands beyond a pathogenic threshold, typically more than 36 repeats, the resulting ataxin-7 protein carries an abnormally long polyglutamine segment. This stretched segment drives the protein to misfold and aggregate, poisoning neurons in the cerebellum, brainstem and, uniquely among the polyglutamine ataxias, the cone and rod photoreceptors of the retina. The landmark cloning of the SCA7 gene in 1997 revealed that the CAG expansion in this disorder is among the most unstable in the human genome, and that instability underlies a notorious genetic phenomenon called anticipation.

Anticipation means that each successive generation can inherit a longer repeat tract than the parent who transmitted it, and because longer repeats generally correlate with earlier onset and more severe disease, children of affected parents may fall ill decades before their parents did. Paternal transmission is classically associated with the most dramatic expansions, and maternally transmitted cases with massive somatic instability have produced infantile-onset disease. Yet repeat length is not the whole story. Studies in transgenic mice have shown that the genomic context surrounding the repeat strongly influences its instability, and clinical experience has repeatedly shown that patients carrying identical repeat lengths can manifest very different symptoms. The new report from Zhengzhou adds compelling human evidence to that murine and statistical picture, documenting how one family under a single roof can display markedly divergent phenotypes from one shared mutation.

The centerpiece of the report is an individual who, in addition to the expected cerebellar ataxia and retinal degeneration characteristic of SCA7, exhibited angioid streaks on fundus examination. Angioid streaks appear as irregular gray or dark red lines radiating from the optic disc, visible because calcified and fragmented Bruch’s membrane allows the underlying choroidal vasculature to show through. They are classically associated with pseudoxanthoma elasticum, Paget’s disease of bone, sickle cell hemoglobinopathies and certain rare metabolic conditions, but they have never been considered a feature of SCA7. The authors documented the streaks with multimodal ophthalmic imaging: color fundus photography captured the radiating lines, fundus autofluorescence revealed corresponding linear hypoautofluorescent changes, and optical coherence tomography showed focal irregularities at the junction of the retinal pigment epithelium and Bruch’s membrane. The convergence of findings across these independent modalities strengthens the case that the structural abnormality was real and not an imaging artifact.

The clinical significance of this observation is twofold. First, angioid streaks are clinically dangerous in their own right because the brittle Bruch’s membrane predisposes patients to choroidal neovascularization, the abnormal ingrowth of fragile blood vessels that can hemorrhage and cause abrupt, severe central vision loss. A recent comprehensive review of angioid streak-related choroidal neovascularization emphasized that early detection and prompt anti-VEGF treatment can preserve vision in these patients. If SCA7 patients can develop angioid streaks, ophthalmologists caring for them may need to add this complication to their surveillance list, distinguishing new vessel growth from the slower cone-rod retinal dystrophy that ordinarily accompanies the disease. Second, from a mechanistic standpoint, the finding raises the question of whether mutant ataxin-7, which is expressed outside the nervous system, might directly or indirectly compromise Bruch’s membrane integrity, or whether the association is coincidental and merely co-occurring in this individual. The authors are appropriately cautious, presenting the case as an expansion of the phenotypic spectrum rather than proof of causation.

Equally instructive is the intrafamilial variability the report documents. A second affected individual in the same kindred showed advanced retinal degeneration with no identifiable angioid streaks at all: fundus photographs revealed diffuse degenerative changes, autofluorescence demonstrated widespread hypoautofluorescence, and OCT confirmed disruption and thinning of the outer retinal layers and retinal pigment epithelium. Two relatives, one mutation, one family environment, and yet two visibly distinct retinal phenotypes. This kind of divergence within a single pedigree is a vivid demonstration that genotype alone does not determine phenotype. Candidate modifiers include the exact repeat length and its somatic instability in different tissues, other genetic variants inherited independently at modifier loci, epigenetic differences, sex, environmental exposures and stochastic developmental events. Longitudinal cohort studies of related ataxias such as SCA1, SCA2, SCA3 and SCA6 have similarly shown that progression rates vary widely even after accounting for repeat length, and recent work on SCA1 has even uncovered sex-specific differences in presentation and progression, reinforcing the growing recognition that hereditary ataxias are shaped by networks of modifiers rather than by a single number in a sequencing report.

For clinicians, the practical message is that SCA7 should be considered a moving target. The disease has already been reported masquerading as Stargardt’s disease, an inherited juvenile macular degeneration, in patients who presented with vision loss before ataxia appeared. Some patients receive their first diagnosis from an ophthalmologist rather than a neurologist because the retina fails before balance does. Adding angioid streaks to the differential expands the diagnostic considerations in both directions: neurologists evaluating a patient with unexplained ataxia who happens to have angioid streaks on fundoscopy may now reasonably order ATXN7 repeat testing, and ophthalmologists encountering angioid streaks of uncertain cause should be alert to subtle cerebellar signs. Genetic testing remains the only definitive diagnostic tool, and the report underscores the value of combining neurological assessment, genetic confirmation and multimodal ophthalmic imaging in the workup of suspected hereditary ataxias.

The molecular biology underlying SCA7 continues to be an active therapeutic frontier. Because the disease is caused by a toxic gain of function from the expanded protein, strategies under investigation include antisense oligonucleotides designed to reduce ataxin-7 production, RNA interference approaches, gene editing to trim the repeat tract, and small molecules aimed at stabilizing the transcriptional machinery that mutant ataxin-7 disrupts. Understanding the full range of tissues affected matters for these efforts. If retinal structures beyond photoreceptors, such as Bruch’s membrane and the retinal pigment epithelium, can be drawn into the disease process, then delivery of any future therapy must reach not only cerebellar neurons but also the posterior segment of the eye, a compartment with its own pharmacological barriers. Detailed phenotyping of rare cases, as performed here, helps define the true therapeutic target list.

The study itself was a modest but careful piece of clinical science. Conducted at a single center in Zhengzhou with funding from Henan provincial research programs, it involved detailed collection and integration of clinical, genetic and imaging data, with all participants or their legal guardians providing written informed consent and the protocol approved under the Declaration of Helsinki. The authors, Chunyan Cao, Shang Xu, Yaqiong Li and Jiewen Zhang, conceived the study, assembled the data and interpreted the findings collaboratively, and they acknowledge that the observations require replication in larger cohorts before the association can be considered established. Data supporting the findings are available from the corresponding author upon reasonable request.

Rare observations like these are often dismissed as curiosities, yet history shows that they can redefine how diseases are understood and detected. Every expanded phenotypic spectrum shortens the diagnostic odyssey for someone, because a physician who has read that SCA7 can produce angioid streaks will think to test for it sooner. Every documented instance of intrafamilial variability strengthens the scientific case for hunting genetic modifiers, which in turn may reveal new therapeutic targets applicable beyond the rare families in which they are found. As gene-based therapies for polyglutamine disorders edge closer to the clinic, the precision with which the medical community can recognize every face these diseases present becomes not merely an academic exercise but a prerequisite for treating patients early enough to matter. This single family in Henan Province, examined with modern genetics and multimodal retinal imaging, has added one more facet to that recognition effort, and it is a reminder that even the best-characterized Mendelian diseases still hold surprises.

Subject of Research: Phenotypic expansion of spinocerebellar ataxia type 7, including angioid streaks and intrafamilial clinical variability

Article Title: Expanding the phenotypic spectrum of spinocerebellar ataxia type 7: angioid streaks and intrafamilial phenotypic variability

Article References: Cao, C., Xu, S., Li, Y., & Zhang, J. (2026). Expanding the phenotypic spectrum of spinocerebellar ataxia type 7: angioid streaks and intrafamilial phenotypic variability. Journal of Neurology, 273(10), Article 589. https://doi.org/10.1007/s00415-026-14081-9

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14081-9

Keywords: spinocerebellar ataxia type 7, ATXN7, CAG repeat expansion, angioid streaks, phenotypic variability, retinal degeneration, cone-rod dystrophy, Bruch's membrane, genetic anticipation, hereditary ataxia, multimodal retinal imaging, choroidal neovascularization

The central insight behind optogenetic therapy is elegantly simple. In advanced retinal degenerative diseases such as retinitis pigmentosa and end-stage age-related macular degeneration, the photoreceptors that normally convert light into electrical signals have degenerated, leaving the rest of the retinal circuitry largely intact but functionally dark. Conventional gene replacement therapy, which works by delivering a healthy copy of a single defective gene, is no longer applicable once the target cells are gone, particularly because these diseases can be caused by mutations in dozens of different genes. Optogenetics sidesteps this problem entirely: it is mutation-agnostic. By using viral vectors to deliver genes encoding light-sensitive proteins called opsins into whatever neurons remain, the therapy converts those cells into artificial photoreceptors capable of responding to light directly.

The technical foundation of the field was established in the mid-2000s, when researchers demonstrated that channelrhodopsin-2, a directly light-gated cation channel originally discovered in algae, could be expressed in neurons to control their activity with millisecond precision. Early proof-of-concept studies showed that ectopic expression of microbial-type rhodopsins could restore visual responses in mice with photoreceptor degeneration, and landmark work soon extended this approach to ON bipolar cells and to dormant cone photoreceptors in models of retinitis pigmentosa. What began as a neuroscience tool for controlling neural activity has since evolved into a therapeutic platform, with the retina emerging as arguably the most clinically advanced target for optogenetics in the entire human body.

One of the most consequential decisions in any optogenetic therapy is which retinal cell type to target. The review devotes detailed attention to this question, weighing the merits of retinal ganglion cells, bipolar cells, and residual cone photoreceptors. Ganglion cells, the output neurons of the retina, are readily accessible from the vitreous and survive late into degeneration, but targeting them means bypassing the retina’s internal image-processing circuitry entirely. Bipolar cells sit one synapse upstream and offer the possibility of preserving some of the retina’s native signal processing, potentially yielding better spatial resolution and more natural vision. Residual cones, even when metabolically compromised, can in principle be genetically reactivated and their existing downstream wiring exploited. Each strategy involves distinct trade-offs between accessibility, image fidelity, and light sensitivity, and no single approach has yet emerged as definitively superior.

Opsin engineering itself has progressed dramatically. First-generation tools such as channelrhodopsin-2 respond only to high-intensity blue light, far brighter than ambient levels, which is a fundamental problem for a therapy intended to work under everyday conditions. Subsequent generations have addressed this through several routes: microbial opsins with enhanced sensitivity, animal cone rhodopsins that exploit the retina’s natural biochemical amplification cascades, and engineered multicharacteristic opsins designed to combine fast kinetics, broad spectral sensitivity, and high responsiveness. Chimeric rhodopsins have shown highly sensitive visual restoration and even neuroprotective effects in mouse models, while rhodopsin-based approaches have demonstrated that enhanced sensitivity and adaptation can be achieved by recruiting the native phototransduction machinery. The review emphasizes that light sensitivity remains perhaps the single most important determinant of whether laboratory success translates into meaningful patient benefit.

Delivering these genes to the right cells presents its own formidable engineering challenge, and the review provides a thorough account of the viral vector platforms underpinning retinal gene delivery. Adeno-associated virus, or AAV, has become the workhorse of retinal gene therapy thanks to its safety profile, durability, and natural ocular tropism. Engineered capsids such as AAV7m8 and the directed-evolution variant AAV8BP2 have enabled efficient outer retinal gene delivery from a simple intravitreal injection, avoiding the surgical risks of subretinal administration. Yet AAV’s roughly 4.7-kilobase packaging limit constrains how large an opsin gene, promoter, and regulatory elements can be squeezed into a single vector. Creative solutions, including intein-mediated protein trans-splicing that splits large proteins across two vectors and reconstitutes them inside the target cell, are expanding what is possible, while cell-specific promoters drawn from retinal ganglion cell and bipolar cell biology sharpen targeting precision.

The clinical pipeline reflects this maturation. A watershed moment came in 2021, when researchers reported partial recovery of visual function in a blind patient with retinitis pigmentosa after optogenetic therapy using the opsin ChrimsonR combined with image-transmitting goggles, the first reported functional benefit in a human. Since then, multiple clinical trials have advanced worldwide, including studies of AAV-based RGS-optimized therapies, the STARLIGHT phase 2 trial of MCO-010 multicharacteristic opsin therapy in patients with Stargardt disease, and trials of programs including GS030, BS01, ZM-02 and RV-01 targeting advanced retinitis pigmentosa. Work in non-human primates has demonstrated high spatiotemporal resolution and pattern discrimination compatible with genuine vision restoration, providing critical evidence that the approach can scale from rodents to human-sized eyes.

Yet the review is notably candid about the barriers that remain. Interspecies differences loom large: the mouse retina, the workhorse of preclinical optogenetics, differs radically from the human retina in cell numbers, photoreceptor topography, and internal anatomy, meaning promising rodent results do not guarantee human efficacy. The primate eye poses additional physical barriers, including the internal limiting membrane and the vitreoretinal interface, which impede vector penetration from the vitreous. Immune responses represent another serious concern, both to AAV capsids, which many patients have already encountered naturally, and to the microbial opsin proteins themselves, which the human immune system may recognize as foreign. Neural remodeling in the degenerated retina further complicates matters, as surviving circuits rewire in ways that may distort or degrade the signals delivered by engineered photosensitivity.

Perhaps less appreciated, but equally consequential, are the drug-development and regulatory hurdles. Patients with profound visual impairment present unique challenges for clinical trial design, and the field currently lacks standardized, validated clinical endpoints for measuring meaningful visual improvement in people with end-stage retinal degeneration. Traditional visual acuity measures are largely useless at these levels of vision loss, forcing investigators to develop novel outcome measures, from light-perception tasks to mobility and object-recognition tests, and to work closely with regulatory agencies and patient advocacy groups to define what constitutes a clinically meaningful benefit in a rare-disease population.

The review concludes that addressing these barriers is essential to establishing optogenetics as a clinically viable therapeutic modality and to enabling next-generation vision restoration. The trajectory is nonetheless striking: in barely two decades, optogenetics has moved from millisecond optical control of neurons in a dish to a growing international clinical pipeline offering realistic hope to patients for whom no other treatment exists. As opsin sensitivity improves, engineered capsids deliver genes more safely and precisely, and clinical endpoints mature, the prospect of restoring useful vision to millions of people blinded by photoreceptor degeneration is shifting from speculative ambition to an achievable clinical goal, one light-sensitive cell at a time.

Subject of Research: Optogenetic gene therapy for restoring vision in advanced retinal degenerative diseases

Article Title: Optogenetic vision restoration: translational barriers and emerging therapeutic strategies

Article References: Nakada, N. (2026). Optogenetic vision restoration: translational barriers and emerging therapeutic strategies. Gene Therapy. https://doi.org/10.1038/s41434-026-00640-2

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00640-2

Keywords: optogenetics, vision restoration, gene therapy, retinitis pigmentosa, retinal degeneration, opsins, adeno-associated virus, retinal ganglion cells, bipolar cells, photoreceptors, clinical trials, blindness